期刊文献+

老年急性冠状动脉综合征早期血浆组织因子及其途径抑制物2的变化规律 被引量:1

Changes of plasma tissue factor and tissue factor pathway inhibitor 2 levels in elderly patients with acute coronary syndrome
下载PDF
导出
摘要 目的观察老年急性冠状动脉综合征(ACS)患者在病程早期的血浆组织因子(TF)、基质金属蛋白酶(MMP)-1水平,以及组织因子途径抑制物(TFPI)-2的变化规律,探讨TFPI-2在ACS发病机制及病情监测中的意义。方法连续入选2008年3月—2009年3月在复旦大学附属华山、华东医院住院,年龄≥60岁的患者,根据临床表现、冠状动脉造影检查结果分别入选ACS组及稳定型心绞痛(SAP)组。冠状动脉造影检查正常的老年健康者入选正常组。ACS组分别于入院24h内及发病后2、4周采集外周静脉血,SAP、正常组于入院24h内采集外周静脉血,采用酶联免疫吸附试验检测血浆TF、TFPI-2及MMP-1水平,计算TF/TFPI-2比值。结果共纳入176例患者,ACS组96例,SAP组50例及正常组30例。各组间年龄,性别构成,高血压、吸烟、糖尿病构成比,低密度脂蛋白胆固醇、三酰甘油水平,他汀类药物及血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂使用率的差异均无统计学意义(P值均>0.05),ACS组的高密度脂蛋白胆固醇、左心室射血分数(LVEF)均显著低于SAP组和正常组(P值均<0.05),而血肌酐(sCr)、超敏C反应蛋白(hsCRP)均显著高于SAP组和正常组(P值均<0.05)。发病24h时,与SAP组和正常组相比,ACS组的TFPI-2水平显著降低(P值均<0.05),而TF、MMP-1水平及TF/TFPI-2比值均显著升高(P值均<0.05)。ACS组中,TF水平随病程的延长而逐步降低(P值均<0.05),TFPI-2水平随病程的延长而先升高,然后降低(P值均<0.05)。Logistic多元回归分析显示,血浆TFPI-2和LVEF下降以及血浆TF、MMP-1和hsCRP水平升高与ACS的发病相关(P值均<0.05)。结论老年ACS患者在病程早期的血浆TFPI-2水平较低,而TF、MMP-1水平较高,提示TFPI-2的分泌不足可能参与ACS的发病。 Objective To measure the levels of plasma tissue factor (TF), matrix metalloproteinase 1 (MMP-1) and tissue factor pathway inhibitor-2 (TFPI-2) in the early stage of acute coronary syndrome (ACS) in elderly patients, and to investigate the role of TFPI-2 in the process of ACS and possibility of TFPI-2 as a early plasma markers for ACS. Methods A consecutive series of in-hospital patients (age≥60 years old) in Huashan Hospital and Huadong Hospital between March 2008 and March 2009 were enrolled in this study. The patients were diagnosed as ACS and stable angina pectoris (SAP) according to clinical manifestation and coronary angiogram (CAG). The patients with normal CAG results were set as control group. Venous blood samples were obtained on admission, and at 2 and 4 weeks after symptom onset. Plasma concentrations of TF, TFPI-2 and MMP-1 were measured by enzyme-linked immunosorbent assay (ELISA) and the ratio of TF to TFPI-2 was calculated. Results A total of 176 patients were enrolled in the study (96 with ACS, 50 with SAP and 30 with normal coronary arteries). There were no statistical differences in age, gender, hypertension, smoking, diabetes, low density lipoprotein, triglyceride or medication including statins and angiotensin converting enzyme inhibitors (ACEI)/ angiotensin receptor blocker (ARB) among three groups (all P〈0. 05). High density lipoprotein and left ventricular ejection fraction (LVEF) in ACS group were significantly lower than those in SAP and control groups, while serum creatinine and high sensitive C reactive protein (hsORP) in ACS group were significantly higher than those in SAP and control groups (P〈0.05). On admission, TF and MMP-1 levels and the ratio of TF to TFPI-2 were significantly increased while TFPI-2 was significantly decreased in ACS group as compared with SAP and control groups (all P〈0.05). In the ACS group, TF was decreased and TFPI-2 was elevated gradually and then declined as the disease developed (all P〈0.05). Multivariate logistic regression analysis revealed that a low level of TFPI-2 on admission was an independent factor related to the development of ACS, along with low LVEF, and high TF, MMP-1 and hsCRP levels (all P〈0.05). Conclusion In the early stage of ACS, elderly patients have low level of TFPI-2 and high levels of TF and MMP-1, implying that the lack of TFPI-2 may be related to ACS.
出处 《上海医学》 CAS CSCD 北大核心 2012年第9期779-783,共5页 Shanghai Medical Journal
基金 上海市卫生局科研基金资助项目(2007100)
关键词 急性冠状动脉综合征 组织因子途径抑制物2 组织因子 基质金属蛋白酶 Acute coronary syndrome Tissue factor pathway inhibitor-2 Tissue factor Matrix metalloproteinase
  • 相关文献

参考文献13

  • 1VAN D E WERF F, BAX J, BETRIU A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology[J]. Eur Heart J, 2008, 29(23): 2909-2945.
  • 2ARDISSINO D, MERLINI P A, ARLENS R, et al. Tissue factor in human coronary atherosclerotic plaques [J]. Clin Chim Acta, 2000, 291(2): 235-240.
  • 3SOEJIMA H, OGAWA H, YASUE H, et al..Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina [J]. Circulation, 1999, 99(22): 2908-2913.
  • 4AL-NOZHA M M, ABDEL-GADER A G, ARAFAH M R, et al. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes[J]. Saudi Med J, 2005, 26 (6) 937-942.
  • 5SABATIER F, ROUX V, ANFOSSO F, et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity [J ]. Blood, 2002, 99(11): 3962-3970.
  • 6INOKUBO Y, HANADA H, ISHIZAKA H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome[J]. Am Heart J, 2001, 141(2).. 211-217.
  • 7PETERSEN L C, SPRECHER C A, FOSTER D C, et al. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor[J]. Biochemistry, 1996, 35(1): 266-272.
  • 8HERMAN M P, SUKHOVA G K, KISIEL W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atheroselerosis[J]. J Clin Invest, 2001, 107(9): 1117-1126.
  • 9HIGASHIKATA T, YAMAGISHI M, HIGASHI T, et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method [J]. Atheroselerosis, 2006, 185(1): 165-172.
  • 10PAN J J, SHI H M, LUO X P, et al. Recombinant TFPI-2 enhances macrophage apoptosis through upregulation of Fas/ FasL[J]. Eur J Pharmaeol, 2011, 654(2) : 135-141.

同被引文献6

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部